Last reviewed · How we verify

Morphine intravenous

Charles University, Czech Republic · FDA-approved active Small molecule

Morphine binds to opioid receptors in the central and peripheral nervous system to produce analgesia, sedation, and euphoria.

Morphine binds to opioid receptors in the central and peripheral nervous system to produce analgesia, sedation, and euphoria. Used for Acute moderate to severe pain, Postoperative pain, Cancer pain.

At a glance

Generic nameMorphine intravenous
Also known asMorphine and patient controlled analgesia
SponsorCharles University, Czech Republic
Drug classOpioid analgesic
TargetMu-opioid receptor (μ-OR)
ModalitySmall molecule
Therapeutic areaPain management
PhaseFDA-approved

Mechanism of action

Morphine is a mu-opioid receptor agonist that crosses the blood-brain barrier and acts on opioid receptors in the brain, spinal cord, and peripheral tissues. This binding modulates pain perception, reduces anxiety, and produces sedation. The intravenous formulation provides rapid onset of action for acute pain management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results